EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis

Harold E Bays iD, LeAnne Bloedon, Danielle Brennan, Lei Lei, A Michael Lincoff iD, Stephen J Nicholls, Jorge Plutzky iD, Heather A Powell, Steven E Nissen iD

Journal of the American Heart Association · 18.02.2025 · 14 (4)

DOI: 10.1161/jaha.124.037898 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 18.02.2025. Verfasst von Harold E Bays und 8 weiteren Autor:innen. Beteiligte Einrichtung: Louisville Metabolic and Atherosclerosis Research Center Louisville KY. Hauptthemen laut MEDLINE: Obesity, Dicarboxylic Acids, Cardiovascular Diseases, Fatty Acids. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity and hypercholesterolemia independently increase cardiovascular disease risk. This analysis evaluated the efficacy and safety of bempedoic acid in people with obesity participating in the CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL‐Inhibiting Regimen) Outcomes trial.

Methods

CLEAR Outcomes randomized 13 970 patients to daily bempedoic acid 180 mg or placebo. Exploratory outcomes including major adverse cardiovascular events‐4 (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization), low‐density lipoprotein cholesterol, hs‐CRP (high‐sensitivity C‐reactive protein), weight change, and safety were assessed over a median of 40.7 months in 6177 patients with baseline body mass index ≥30 kg/m 2 .

Results

In people with obesity, bempedoic acid resulted in placebo‐corrected reductions in low‐density lipoprotein cholesterol of −22.5% and hs‐CRP of −23.2% at 6 months. Bempedoic acid treatment resulted in a major adverse cardiovascular events‐4 reduction of 23% (hazard ratio [HR], 0.77 [95% CI, 0.67–0.89]) versus placebo. Nonfatal and fatal MI were reduced by 32% (HR, 0.68 [95% CI, 0.53–0.86]), coronary revascularization was reduced by 24% (HR, 0.76 [95% CI, 0.63–0.92]), and fatal and nonfatal stroke were reduced by 36% (HR, 0.64 [95% CI, 0.45–0.89]) compared with placebo. At month 36, mean±SD change in weight from baseline was −2.3 (6.3) kg for bempedoic acid and −1.4 (6.1) kg for placebo. Adverse events were reported in 87.4% of bempedoic acid patients and 86.7% of placebo patients. The mean±SD change in uric acid at 6 months was 0.81 (1.26) mg/dL for bempedoic acid versus −0.04 (1.05) mg/dL for placebo.

Conclusions

Among people with obesity, bempedoic acid reduced major adverse cardiovascular events, low‐density lipoprotein cholesterol, and hs‐CRP, with a safety profile consistent with previous reports. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02993406.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityDicarboxylic AcidsCardiovascular DiseasesFatty AcidsAnticholesteremic AgentsHumansMaleFemaleMiddle AgedTreatment OutcomeAgedC-Reactive ProteinCholesterol, LDLDouble-Blind MethodBiomarkersAdult

Stichwörter der Autor:innen

bempedoic acidcardiovascular diseasecardiovascular risklipid loweringobesitystatin intolerance

Substanzen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty AcidsC-Reactive ProteinCholesterol, LDLAnticholesteremic AgentsBiomarkers

Autor:innen und Institutionen

  • Louisville Metabolic and Atherosclerosis Research Center Louisville KY.
  • Esperion Therapeutics, Inc. Ann Arbor MI.
  • Cleveland Clinic Cleveland OH.
  • Victorian Heart Institute Monash University Melbourne Australia.
  • Brigham and Women's Hospital, Harvard University Boston MA.

ORCID-Profile: Harold E Bays, A Michael Lincoff, Jorge Plutzky, Steven E Nissen

Zitieren

APA

Bays, H. E., Bloedon, L., Brennan, D., Lei, L., Lincoff, A. M., Nicholls, S. J., Plutzky, J., Powell, H. A., & Nissen, S. E. (2025). Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis. Journal of the American Heart Association, 14(4). https://doi.org/10.1161/jaha.124.037898

Vancouver

Bays HE, Bloedon L, Brennan D, Lei L, Lincoff AM, Nicholls SJ, et al. Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis. Journal of the American Heart Association. 2025;14(4). doi:10.1161/jaha.124.037898

BibTeX
@article{Bays2025,
  author = {Bays, Harold E and Bloedon, LeAnne and Brennan, Danielle and Lei, Lei and Lincoff, A Michael and Nicholls, Stephen J and Plutzky, Jorge and Powell, Heather A and Nissen, Steven E},
  title = {Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {4},
  doi = {10.1161/jaha.124.037898}
}
Kostenlos starten →